Diabetic foot ulcers (DFU) therapeutics are used for treatment of sores developed on the feet of diabetic patients. These sores develop either due to neuropathic or vascular complication in patients. DFU are common in the U.S. and U.K. where 5-7% of people with diabetes have or have had diabetic foot ulcers. Furthermore, approximately 2 out 10 people with diabetes develop DFU in their lifetime. Therefore, DFUs have a major impact on health and economy in developed as well as developing regions in the world.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/5441
The global diabetic foot ulcers (DFU) therapeutics market is segmented into DFU anti-infective agents and DFU wound healing products. The majorly marketed DFU anti-infective agents include ertapenem, piperacillin + tazobactam and linezolid while becaplermin is the most widely used DFU healing drug. On the basis of geography, the global DFU therapeutics market is segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. North America accounts the major share in the market due to the large number of diabetic population in the U.S. and Canada. The North American market is closely followed by the Europe since prevalence diabetes in this region is also very high.
The major driver for the growth of the global DFU therapeutics market is increasing prevalence of diabetes globally and subsequent rise in incidences of diabetic foot ulcers. The other market driving factors include lower-extremity amputations caused in case of untreated or improper treatment for DFU, decreased quality of life and high medical cost if DFUs are left unattended. Higher costs of the wound-healing agents is the only restraint for the growth of this market as it prevents people in developing nations from treating their diabetic foot ulcers.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/5441
Some of the players in the global diabetic foot ulcer (DFU) therapeutics market are Bridge BioResearch plc, Derma Sciences, Inc., Innocoll, Inc., Olympus Biotech (wholly owned subsidiary of Olympus Corporation), Organogenesis Inc., Shire Regenerative Medicine, Dipexium Pharmaceuticals, LLC, Osiris Therapeutics, and Kaken Pharmaceutical Co., Ltd.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353